# NU Skin Enterprises, Inc.: overview

NUS · NYSE · CIK 1021561 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nus.md) · [Financials](/companies/nus/financials.md) · [Filings](/companies/nus/filings.md) · [Insiders](/companies/nus/insiders.md)

Latest reported revenue: [$320.1m](/filings/0001140361-26-032055.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001140361-26-032055).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [430](/filings/0001140361-25-040839.md) | [446 d](/filings/0001140361-26-005130.md) | [364](/filings/0001140361-26-019630.md) | [386](/filings/0001140361-26-032055.md) | [364](/filings/0001140361-25-040839.md) | [370 d](/filings/0001140361-26-005130.md) | [321](/filings/0001140361-26-019630.md) | [320](/filings/0001140361-26-032055.md) |
| Gross margin | % | [70.1%](/filings/0001140361-25-040839.md) | [62.7% d](/filings/0001140361-26-005130.md) | [67.8%](/filings/0001140361-26-019630.md) | [68.8%](/filings/0001140361-26-032055.md) | [70.5%](/filings/0001140361-25-040839.md) | [70.7% d](/filings/0001140361-26-005130.md) | [66.9%](/filings/0001140361-26-019630.md) | [68.2%](/filings/0001140361-26-032055.md) |
| Operating margin | % | [4.2%](/filings/0001140361-25-040839.md) | [(11.9%) d](/filings/0001140361-26-005130.md) | [(2.7%)](/filings/0001140361-26-019630.md) | [8.0%](/filings/0001140361-26-032055.md) | [5.9%](/filings/0001140361-25-040839.md) | [6.3% d](/filings/0001140361-26-005130.md) | [1.3%](/filings/0001140361-26-019630.md) | [(18.5%)](/filings/0001140361-26-032055.md) |
| Net margin | % | [1.9%](/filings/0001140361-25-040839.md) | [(8.1%) d](/filings/0001140361-26-005130.md) | [29.5%](/filings/0001140361-26-019630.md) | [5.5%](/filings/0001140361-26-032055.md) | [4.7%](/filings/0001140361-25-040839.md) | [3.9% d](/filings/0001140361-26-005130.md) | [0.6%](/filings/0001140361-26-019630.md) | [(78.0%)](/filings/0001140361-26-032055.md) |
| Diluted EPS | $ per share | [0.17](/filings/0001140361-25-040839.md) | not reported | [2.14](/filings/0001140361-26-019630.md) | [0.43](/filings/0001140361-26-032055.md) | [0.34](/filings/0001140361-25-040839.md) | not reported | [0.04](/filings/0001140361-26-019630.md) | [(5.14)](/filings/0001140361-26-032055.md) |
| Free cash flow | $m | [22.8 d](/filings/0001140361-25-040839.md) | [13.2 d](/filings/0001140361-26-005130.md) | [(13.2)](/filings/0001140361-26-019630.md) | [35.8 d](/filings/0001140361-26-032055.md) | [17.6 d](/filings/0001140361-25-040839.md) | [5.9 d](/filings/0001140361-26-005130.md) | [(17.6)](/filings/0001140361-26-019630.md) | [5.0 d](/filings/0001140361-26-032055.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,696](/filings/0001140361-24-008111.md) | [2,226](/filings/0001140361-25-004907.md) | [1,969](/filings/0001140361-26-005130.md) | [1,732](/filings/0001140361-26-005130.md) | [1,485](/filings/0001140361-26-005130.md) |
| Gross margin | % | [75.0%](/filings/0001140361-24-008111.md) | [71.7%](/filings/0001140361-25-004907.md) | [68.9%](/filings/0001140361-26-005130.md) | [68.2%](/filings/0001140361-26-005130.md) | [69.4%](/filings/0001140361-26-005130.md) |
| Operating margin | % | [8.7%](/filings/0001140361-24-008111.md) | [5.0%](/filings/0001140361-25-004907.md) | [2.5%](/filings/0001140361-26-005130.md) | [(8.8%)](/filings/0001140361-26-005130.md) | [4.4%](/filings/0001140361-26-005130.md) |
| Net margin | % | [5.5%](/filings/0001140361-24-008111.md) | [4.7%](/filings/0001140361-25-004907.md) | [0.4%](/filings/0001140361-26-005130.md) | [(8.5%)](/filings/0001140361-26-005130.md) | [10.8%](/filings/0001140361-26-005130.md) |
| Diluted EPS | $ per share | [2.86](/filings/0001140361-24-008111.md) | [2.07](/filings/0001140361-25-004907.md) | [0.17](/filings/0001140361-26-005130.md) | [(2.95)](/filings/0001140361-26-005130.md) | [3.18](/filings/0001140361-26-005130.md) |
| Free cash flow | $m | [73.0](/filings/0001140361-24-008111.md) | [49.0](/filings/0001140361-25-004907.md) | [60.1](/filings/0001140361-26-005130.md) | [70.2](/filings/0001140361-26-005130.md) | [46.0](/filings/0001140361-26-005130.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nus/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $22.8m | 4,315,878 |  | Added +24,615 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $12.2m | 2,301,308 |  | Added +280,106 |
| [Coppell Advisory Solutions LLC](/funds/1848433.md) | 2026-06-30 | $11.3m | 235 |  | New +235 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.8m | 2,049,641 |  | Reduced −13,709 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $9.5m | 1,796,745 |  | Added +61,563 |
| [Prescott Group Capital Management, L.L.C.](/funds/1166152.md) | 2026-06-30 | $9.5m | 1,794,608 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $9.2m | 1,736,856 |  | Added +27,303 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $8.5m | 1,607,692 |  | Reduced −92,804 |
| [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $7.7m | 1,452,937 |  | Reduced −690,357 |
| [CastleKnight Management LP](/funds/1835751.md) | 2026-06-30 | $7.3m | 1,389,633 |  | Added +424,200 |

## Recent filings

[All 1,435 filings](/companies/nus/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-21 | 16:06 ET | [8-K](/filings/0001140361-26-034016.md) | 5.02 Departure or appointment of officers or directors | 0001140361-26-034016 |
| 2026-08-10 | 17:05 ET | [10-Q](/filings/0001140361-26-032055.md) | Quarterly report, period 2026-06-30 | 0001140361-26-032055 |
| 2026-08-10 | 16:15 ET | [8-K](/filings/0001140361-26-032025.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-032025 |
| 2026-05-29 | 16:05 ET | [8-K](/filings/0001140361-26-023312.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-26-023312 |
| 2026-05-08 | 16:06 ET | [8-K](/filings/0001140361-26-020028.md) | 5.02 Departure or appointment of officers or directors | 0001140361-26-020028 |
| 2026-05-08 | 20:04 ET | [10-Q](/filings/0001140361-26-019630.md) | Quarterly report, period 2026-03-31 | 0001140361-26-019630 |
| 2026-05-07 | 17:09 ET | [8-K](/filings/0001140361-26-019586.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-019586 |
| 2026-04-03 | 14:28 ET | [DEF 14A](/filings/0001140361-26-013152.md) | Proxy statement, period 2026-05-28 | 0001140361-26-013152 |
| 2026-03-27 | 16:34 ET | [8-K](/filings/0001140361-26-011757.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001140361-26-011757 |
| 2026-03-20 | 16:16 ET | [8-K](/filings/0001140361-26-010559.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-010559 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001140361-26-005130.md), filed Feb 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/409ccfe9-b085-4c35-b545-e78c0c3cabfa)

## About the filer

- CIK: 1021561
- Tickers: NUS
- Exchange: NYSE
- SIC code: 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.